Micropos Medical
Enabling accuracy in prostate cancer care
Micropos Medical is a Swedish medical device company that develops, manufactures, and sells technology enabling enhanced radiotherapy cancer treatment. Its product Raypilot® System, generates high precision as well as high efficiency through real-time tumour tracking in radiation treatment of prostate cancer. Raypilot is marketed in Europe and the US.
The Micropos Medical share is traded under the stock ticker MPOS on the Spotlight Stock Market.
For more information about the share, please visit Spotlight
Interim Reports
- Micropos Year End Report 2022
- Micropos Q3 Report 2022
- Micropos Half Year Report 2022
- Micropos Q1 Report 2022
- Micropos Year End Report 2021
- Micropos Q3 Report 2021
- Micropos Half Year Report 2021
- Micropos Q1 Report 2021
- Micropos Q3 Report 2020
- Micropos Half Year Report 2020
- Micropos Q1 Report 2020
- Micropos Half Year Report 2019
- Micropos Half Year Report 2018
- Micropos Half Year Report 2017
- Micropos Half Year Report 2016
- Micropos Q1 Report 2015
annual reports
- Micropos Annual Report 2021
- Micropos Annual Report 2020
- Micropos Annual Report 2019
- Micropos Annual Report 2018
- Micropos Annual Report 2017
- Micropos Annual Report 2016
- Micropos Annual Report 2015
- Micropos Annual Report 2014
- Micropos Annual Report 2013
- Micropos Annual Report 2012
- Micropos Annual Report 2011
IR CALENDAR
- 30 January 2023 – Year-end report 2022
- 27 April 2023 – Interim report Q1 2023
- 27 July 2023 – Interim report Q2 2023
- 26 October 2023 – Interim report Q3 2023
- 31 January 2024 – Interim report Q4 2023
For additional information, please contact:
Thomas Lindström, CEO, Micropos Medical AB (publ)
+46-31-760 80 05, info@micropos.se
-
news
Bokslutskommuniké 2022 är nu publicerad
Micropos Medicals Bokslutskommuniké 2022, Kvartalsrapport Q4, finns nu publicerad.
COMPANY INFO
LEARN MORE ABOUT OUR TEAM, BOARD AND OUR PRODUCTS

Follow us on LinkedIn
Let’s keep in touch